WO2016145608A1 - Petit arn activateur, procédé de fabrication et application de ce dernier - Google Patents

Petit arn activateur, procédé de fabrication et application de ce dernier Download PDF

Info

Publication number
WO2016145608A1
WO2016145608A1 PCT/CN2015/074358 CN2015074358W WO2016145608A1 WO 2016145608 A1 WO2016145608 A1 WO 2016145608A1 CN 2015074358 W CN2015074358 W CN 2015074358W WO 2016145608 A1 WO2016145608 A1 WO 2016145608A1
Authority
WO
WIPO (PCT)
Prior art keywords
sequence
seq
antisense
sense
sense sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CN2015/074358
Other languages
English (en)
Chinese (zh)
Inventor
李龙承
龙波
郭丹
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Peking Union Medical College Hospital Chinese Academy of Medical Sciences
Original Assignee
Peking Union Medical College Hospital Chinese Academy of Medical Sciences
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Peking Union Medical College Hospital Chinese Academy of Medical Sciences filed Critical Peking Union Medical College Hospital Chinese Academy of Medical Sciences
Priority to PCT/CN2015/074358 priority Critical patent/WO2016145608A1/fr
Publication of WO2016145608A1 publication Critical patent/WO2016145608A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing

Definitions

  • the invention relates to the field of molecular biology, in particular to the application of double-stranded small RNA in the field of RNA activation technology.
  • RNA interference a small RNA molecule called small Interfering RNA (siRNA). Since siRNA is capable of specifically silencing the expression of a target gene, it is considered to be very promising to develop a new gene-targeted drug for treating diseases.
  • RNA interference is triggered by endogenous dsRNA molecules or by exogenous introduction of siRNA. Endogenous dsRNA is processed by a longer single-stranded RNA that is processed by a protein called Dicer in the cell after it forms a hairpin structure.
  • RNA interference introduction of mature siRNA into cells from outside the cell can also trigger RNA interference.
  • These mature dsRNAs are loaded intracellularly with a protein called Argonaute (AGO), which then directs AGO to bind to mRNA sequences complementary to the intracellular sequence, which in turn cleaves and degrades mRNA, resulting in silencing of gene expression.
  • AGO Argonaute
  • dsRNA targeting gene regulatory sequences such as promoters can trigger the exact opposite of RNA interference, ie increasing gene expression at the transcriptional and epigenetic levels of the gene, and naming the phenomenon as RNA activation (RNAa), This small RNA against a gene promoter is called a small activating RNA (saRNA).
  • the saRNA is a small double-stranded RNA having a length of 21 nucleosides (nt) and a 2 nucleotide deoxyribonucleic acid (DNA) overhang at the 3' end.
  • the AGO protein is also required to participate in its action, and a saRNA-AGO complex is formed with AGO. After the complex enters the nucleus, it binds to a target site on the chromosome, for example, binds to the promoter region of the gene, and then the AGO protein.
  • RNA-mediated transcriptional activation (RITA) ultimately triggers the increase of gene transcription and epigenetic activation.
  • saRNA is also present in the cell.
  • a typical example is a microRNA (miRNA) of 20-26 nucleotides in length. miRNAs are transcribed from the genome to produce primary miRNAs ranging in length from 80 to several thousand nucleotides. After treatment with the Drosha/DGCR8 complex, the original miRNA becomes a miRNA precursor (precursor miRNA) of approximately 80 nucleotides in length.
  • RNA activation can purposely activate gene expression, RNA activation can be used as a molecular tool to study gene function, treat various diseases such as cancer, and reprogram cells.
  • the saRNA molecule comprises a ribonucleotide molecule that is complementary to a non-coding region of the gene.
  • the region where the saRNA binds is selected to activate the expression of the gene.
  • the complementary region of the nucleotide molecule is greater than 14 bases and less than 21 bases.
  • a saRNA molecule is a double-stranded molecule whose second strand is complementary to the first strand to form a double strand with at least two overhanging bases at the 3' end of the two strands.
  • the saRNA molecule can also exist as a single-stranded molecule which can form a double-stranded structure.
  • the first partial region of the single-stranded nucleic acid molecule consists of ribonucleotides and is complementary to the non-coding region of the gene of interest, and the second partial region is complementary to the first partial region to form a double-stranded structure.
  • the saRNA molecules designed according to the above patent application have the following problems: 1) the design efficiency is not high, the success rate of designing the saRNA according to the above saRNA design rule is only 10% to 20%; 2) the saRNA pair designed according to the above saRNA design rule Target gene activation is ineffective.
  • RNA activation there is currently a problem of inefficient RNA activation for many genes. On the one hand, it may be because saRNA needs to enter the nucleus; on the other hand, it may be that the saRNA of the prior art design is still quite different from the sequence composition and chemical structure of the endogenous naturally occurring saRNA.
  • the present application provides a design method of dsaRNA to improve the efficiency of RNA activation and expand the use of RNA activation.
  • the saRNA according to the present invention is substantially a saRNA (dese substrate saRNA, dsaRNA) as a Dicer substrate, and the inventors of the present invention named it Dicer substrate saRNA in order to distinguish it from the prior art saRNA, unless otherwise specified.
  • the saRNA as a Dicer substrate in the present invention is represented by dsaRNA.
  • a small activating RNA consisting of a sense sequence comprising 25 to 30 nucleotides and an antisense sequence comprising 25 to 30 nucleotides, at least 80% of the sequence of the antisense sequence being associated with the sense
  • the sequence is complementary; the sense sequence or the antisense sequence comprises a matching fragment having 19 to 25 nucleotides, At least 80% of the sequences in the matched fragments match the target sites of the target gene regulatory sequences.
  • the target gene regulatory sequence of the present invention refers to a DNA sequence located on DNA in the nucleus, which enhances transcription initiation or elongation, or can positively regulate gene transcription through epigenetic mechanisms.
  • the sense sequence and/or the antisense sequence further comprises 1-5 deoxyribonucleotides; preferably, the 2 nucleotides located at the 3' end of the sense sequence and/or the antisense sequence are Deoxyribonucleotides.
  • the target gene regulatory sequence fragment is a target gene promoter sequence fragment; preferably, the target gene promoter sequence fragment is selected from the first 5000 bases upstream from the transcription start point of the target gene to be transcribed from the target gene.
  • the promoter region formed by the previous base from the beginning Applicants have found in the study that because this region contains specific sequences required for gene transcription, including RNA polymerase or transcription factor binding sites, dsaRNA designed for this region has a higher activation efficiency.
  • the target gene of the dsaRNA is the human gene p21; preferably, the target sequence of the target gene is selected from the group consisting of SEQ ID NO: 64, SEQ ID NO: 65, SEQ ID NO: 66 SEQ ID NO: 67, SEQ ID NO: 68 or SEQ ID NO: 69.
  • the sense and antisense sequences of the dsaRNA are selected from one of the following combinations:
  • the sense sequence is SEQ ID NO: 2, and the antisense sequence is SEQ ID NO: 3;
  • the sense sequence is SEQ ID NO: 4, and the antisense sequence is SEQ ID NO: 5;
  • the sense sequence is SEQ ID NO: 6, and the antisense sequence is SEQ ID NO: 7;
  • the sense sequence is SEQ ID NO: 8
  • the antisense sequence is SEQ ID NO: 9;
  • the sense sequence is SEQ ID NO: 10 and the antisense sequence is SEQ ID NO: 11;
  • the sense sequence is SEQ ID NO: 12 and the antisense sequence is SEQ ID NO: 13.
  • the target gene is the human pancreatic-duodenal homeobox gene PDX1; preferably, the dsaRNA is directed against the human pancreatic-duodenal homeobox gene PDX1
  • sequence and antisense sequences are selected from one of the following combinations:
  • the sense sequence is SEQ ID NO: 54, and the antisense sequence is SEQ ID NO: 55;
  • the sense sequence is SEQ ID NO: 56 and the antisense sequence is SEQ ID NO: 57;
  • the sense sequence is SEQ ID NO: 58, and the antisense sequence is SEQ ID NO: 59;
  • the sense sequence is SEQ ID NO: 60 and the antisense sequence is SEQ ID NO: 61;
  • the sense sequence is SEQ ID NO: 62 and the antisense sequence is SEQ ID NO: 63.
  • the target gene is the human gene NKX3.1; preferably, the sense sequence and the antisense sequence for the small activating RNA of the gene NKX3.1 are selected from one of the following combinations:
  • the sense sequence is SEQ ID NO: 70 and the antisense sequence is SEQ ID NO: 71;
  • the sense sequence is SEQ ID NO: 72 and the antisense sequence is SEQ ID NO: 73;
  • the sense sequence is SEQ ID NO: 74 and the antisense sequence is SEQ ID NO: 75;
  • the sense sequence is SEQ ID NO: 76 and the antisense sequence is SEQ ID NO: 77;
  • the sense sequence is SEQ ID NO:78 and the antisense sequence is SEQ ID NO:79.
  • the invention further provides a method for preparing the small activated RNA described above, the method comprising the steps of:
  • step 2) synthesizing the nucleotide sequence corresponding to the target site described in the step 1) as a base sequence, adding nucleotides to the length of 25 to 30 nt on both sides of the base sequence to obtain a sense sequence;
  • step 4 Combine the sense sequence obtained in step 2) with the antisense sequence obtained in step 3) in the same molar number in RNA annealing buffer, heat to 97 ° C, and then naturally cool to room temperature to obtain double-stranded small activation. RNA.
  • step 2) 1 to 5 deoxyribonucleotides are added when synthesizing the sense sequence and/or the antisense sequence; preferably, the sense sequence and/or the The two nucleotides located at the 3' end of the sense sequence are deoxyribonucleotides.
  • the small activating RNA according to the present invention can be applied to the preparation of a drug for increasing the expression of a target gene, preferably for the preparation of an antitumor drug.
  • the invention also provides a method of increasing the expression of a target gene, the method comprising introducing a small activating RNA as a Dicer substrate according to the invention into a cell of a subject.
  • the present invention provides a method of preventing and/or treating a tumor comprising introducing a small activating RNA as a Dicer substrate according to the present invention into a subject having a tumor risk and/or having a tumor
  • the tumor is selected from the group consisting of bladder cancer, prostate cancer, and liver cancer.
  • the inventors of the present invention found in the study that the cells store endogenous double-stranded small RNAs which are produced by processing a longer single-stranded RNA through multiple steps. These processes require the participation of multiple RNases.
  • the last step is that the RNA containing the hairpin structure of about 27-70 nucleotides is treated with a protein called Dicer. A mature double-stranded small RNA comprising 21-22 nucleotides is generated.
  • the present inventors have found in the study that by designing and synthesizing a dsaRNA longer than the 21 nucleotide saRNA in the prior art, when the dsaRNA is introduced into the cell, the applicant finds that they are treated by the Dicer enzyme to generate a more Natural saRNA can thus more effectively mimic the natural maturation process of endogenous double-stranded small RNA and effectively increase the efficiency of RNA activation.
  • Figures 1a-b are the position and sequence information of dsaP21 prepared according to the present invention on the p21 gene promoter.
  • Figure 1a shows the distribution of dsaP21 in the human p21 promoter region.
  • Figure 1b shows the designed double-stranded sequence information of the dsaP21 nucleic acid (black bold bases represent deoxyribonucleotides).
  • Figure 2 is a bar graph showing the effect of dsaRNA-activated p21 mRNA expression prepared according to the present invention.
  • Figure 3 is a bar graph showing the effect of dsaRNA-activated p21 mRNA expression prepared according to the present invention.
  • Figure 4 is a bar graph showing the effect of applying dsaP21 prepared according to the present invention to inhibit tumor cell growth, indicating that dsaRNA can effectively inhibit tumor cell growth.
  • Figure 5 is a cell morphology diagram of inhibiting tumor cell growth after transfection of dsaP21 prepared by the present invention into PC-3 cells, indicating that dsaRNA can effectively inhibit tumor cell proliferation.
  • Figure 6 is a bar graph showing the effect of activation of p21 mRNA by a nucleic acid molecule of 23 nucleotides in length prepared by the present invention.
  • Figure 7 is a bar graph showing the effect of activation of p21 mRNA by a nucleic acid molecule of 35 nucleotides in length prepared by the present invention.
  • Figure 8 is a bar graph showing the effect of dsaPDX1 produced by the present invention on the expression of a non-tumor related gene PDX1 mRNA.
  • Figure 9 is a bar graph showing the effect of dsaNKX3.1 prepared by the present invention on activation of prostate cancer cell line PC-3 mRNA.
  • Figure 10 is a cell morphology diagram of inhibiting tumor cell growth after transfection of dsaNKX3.1 prepared by the present invention into PC-3 cells, indicating that dsaRNA can effectively inhibit tumor cell proliferation.
  • dsaRNA 1.Dicer substrate saRNA (dsaRNA) design:
  • the selection of the target site of the dsaRNA of the present invention is based on the following principles: 1.
  • the selected target sequence is the sense sequence of the gene; 2.
  • the 5' end of the guide RNA strand is bound to the 3' end of the target sequence; 3.
  • the target sequence has a GC content of 40-65%; 4. avoids the target sequence comprising 4 or more consecutive repeat base sequences; 5.
  • the target sequence has a lower thermodynamic stability than the 5' end. 6.
  • the selected target site should avoid CpG islands and high GC regions.
  • the designed target site has a sequence length of 19 to 25 bases.
  • the promoter region of the gene is selected from 5000 bases upstream of the transcription start site to one base before the transcription start site of the gene.
  • a human p21 (CDKN1A) promoter fragment (SEQ ID NO: 1) was downloaded from the ENSEMBL genomic database, and a total of 1000 base pairs (bp) from the -1000 site to the transcription start site.
  • sequence fragment as a template, six saRNA target sites were designed (as shown in Figure 1a). Each target site has a sequence length of 25 bases.
  • the specific names are as follows:
  • dsaP21-1 target sequence SEQ ID NO: 645'-GCTCCAGGTGCTTCTGGGAGAGGTG-3'
  • dsaP21-2 target sequence SEQ ID NO: 655'-GTATTAATGTCATCCTCCTGATCTT-3'
  • dsaP21-3 target sequence SEQ ID NO: 665'-CCTGGAGAGTGCCAACTCATTCTCC-3'
  • dsaP21-4 target sequence SEQ ID NO: 675'-GGATCAGTGGGAATAGAGGTGATAT-3'
  • dsaP21-5 target sequence SEQ ID NO: 685'-CCAGATTTGTGGCTCACTTCGTGGG-3'
  • dsaP21-6 target sequence SEQ ID NO: 695'-TGCCAACTCATTCTCCAAGTAAAAA-3'.
  • the dsaRNA sense sequence and the antisense sequence were synthesized.
  • the first 23 sequences of the sense sequence were ribonucleotides, the last two were deoxyribonucleotides, and the antisense sequence was 27 nucleotides in length, all of which were ribonucleosides. Glycosylate.
  • Location of the target site and synthetic dsaRNA sense and antisense sequences As shown in Figure 1a - Figure 1b.
  • dsaP21-1 sense sequence: SEQ ID NO: 2GCUCCAGGUG CUUCUGGGAG AGGtg; antisense sequence: SEQ ID NO: 3CACGAGGUCC ACGAAGACCC UCUCCAC), dsaP21-2 (sense sequence: SEQ ID NO: 4GUAUUAAUGU CAUCCUCCUG AUCtt; Antisense sequence: SEQ ID NO: 5UACAUAAUUA CAGUAGGAGG ACUAGAA), dsaP21-3 (sense sequence: SEQ ID NO: 6CCUGGAGAGU GCCAACUCAU UCUcc; antisense sequence: SEQ ID NO: 7GAGGACCUCUCACGGUUGAG UAAGAGG), dsaP21-4 (sense sequence: SEQ ID NO: 8 GGAUCAGUGG GAAUAGAGGU GAUat; antisense sequence: 9UCCCUAGUCA CCCUUAUCUC CACUAUA), d
  • the inventors of the present application also designed six standard saRNAs of 21 nucleotides in length corresponding to the above dsaRNA, wherein the two ends of the sense sequence and the antisense sequence are deoxyribonucleotides, and the specific sequence is:
  • saP21-1 (sense sequence: SEQ ID NO: 16 GCUCCAGGUGCUUCUGGGAGAdTdT; antisense sequence: SEQ ID NO: 17UCUCCCAGAAGCACCUGGAGCdTdT).
  • saP21-2 (sense sequence: SEQ ID NO: 18 GUAUUAAUGUCAUCCUCCUGAdTdT; antisense sequence: SEQ ID NO: 19UCAGGAGGAUGACAUUAAUACdTdT).
  • saP21-3 (sense sequence: SEQ ID NO: 20CCUGGAGAGUGCCAACUCAUUdTdT; antisense sequence: 21 AAUGAGUUGGCACUCUCCAGGdTdT).
  • saP21-4 sense sequence: SEQ ID NO: 22 GGAUCAGUGGGAAUAGAGGUGdTdT; antisense sequence: SEQ ID NO: 23 CACCUCUAUUCCCACUGAUCCdTdT).
  • saP21-5 sense sequence: SEQ ID NO: 24 CCAGAUUUGUGGCUCACUUCGdTdT; antisense sequence: SEQ ID NO: 25 CGAAGUGAGCCACAAAUCUGGdTdT).
  • saP21-6 sense sequence: SEQ ID NO: 26 UGCCAACUCAUUCUCCAAGUAdTdT; antisense sequence: SEQ ID NO: 27 UACUUGGAGAAUGAGUUGGCAdTdT).
  • the exponential growth phase human prostate cancer cell line PC-3 was taken and trypsinized, then suspended in RPMI-1640 medium containing 10% fetal bovine serum, and seeded into 6-well cell culture at a density of 4 ⁇ 10 5 cells/well. Plate, where the medium was 2 ml. 6.25 ⁇ l of dsaRNA at a concentration of 20 ⁇ M was mixed with 243.5 ⁇ l of Opti-MEM medium (purchased from Lifetech), and 5 ⁇ l of Lipofectamine RNAiMax (purchased from Lifetech) was diluted with 245 ⁇ l of Opti-MEM to dilute dsaRNA with RNAiMax. Mix and leave at room temperature for 20 minutes. The transfection mixture (500 ⁇ l) was then added to the cells of the 6-well plate. After mixing well, the cells were placed in a CO 2 incubator and incubated at 37 ° C for 5% CO 2 for 72-96 hours.
  • RNA extraction was performed using the Qiagen RNeasy kit. After 72-96 hours of cell transfection, the medium was removed, the cells were washed with 1 ml of PBS buffer, then 350 ⁇ l of RTL buffer was added, the cell lysate was collected, an equal amount of 70% ethanol was added, and finally 50 ⁇ l of DEPC-treated water was added, and the mixture was collected by centrifugation. RNA. The resulting RNA solution was measured for its concentration using a Nanodrop instrument.
  • RNA Take 1 ⁇ g of RNA, add DEPC to treat water to 10 ⁇ l, add 1 ⁇ l (0.5 ⁇ g) of Oligo-dT primer, incubate at 70 ° C for 10 minutes, transfer to ice, then add 2.5 ⁇ l of RT reaction buffer, 1.0 ⁇ l of 25 mM dNTP, 0.5 ⁇ l of RNA. Enzyme inhibitor, add water to 25 ⁇ l. The reaction was carried out at 45 degrees Celsius for 1 hour and then at 70 degrees Celsius for 10 minutes. Finally, the resulting cDNA was dissolved and diluted to 100 ⁇ l with deRNase water.
  • mRNA expression analysis was performed using a Power Sybrgreen qPCR mixture (purchased from Lifetech) and an ABI 7500 rapid real-time quantitative PCR instrument. 1 ⁇ l of the cDNA product was taken, and 1 ⁇ l of 0.67 ⁇ M primer, 3 ⁇ l of water, and 5 ⁇ l of Sybrgreen reagent were added. The reaction was carried out in a PCR instrument using standard procedures. The GAPDH gene was simultaneously amplified as an internal control.
  • the sense primer is: SEQ ID NO: 285'-ATCACCATCTTCCAGGAGCGA-3'
  • the antisense primer is: SEQ ID NO: 295'-TTCTCCATGGTGGTGAAGACG-3'.
  • Cell transfection was performed in 96-well plates. Cell proliferation is measured using Promega The AQ ueous One Solution Cell Proliferation Assay kit is completed. Cell proliferation assays were performed daily for 0-6 days after cell transfection for a total of 6 time points. 20 ⁇ l of the solution one reagent was added to the culture medium before the analysis, and then the cells were further cultured at 37 ° C for 30 minutes, and the absorbance was measured with a microplate reader at a wavelength of 490 nm.
  • PC-3 tumor cells were uniformly inoculated into 6-well plates, and cells were transfected the next day, and observed under a phase contrast microscope at 72 hours after transfection and photographed.
  • RNAa 1.dsaRNA triggers RNAa
  • RNAa activity of dsaRNA PC-3 cells were transfected with dsaRNA, Mock and dsaControl were used as controls, and dsaControl was used as a control for non-specific dsaRNA, a molecule that was not complementary to any gene sequence in the cell. .
  • the cells were harvested 72 hours after transfection, and total RNA was extracted, and cDNA was obtained by reverse transcription reaction.
  • cDNA was amplified by real-time quantitative PCR using human p21 gene primer, and GAPDH was amplified as an internal control.
  • 3 (dsaP21-4, dsaP21-5, dsaP21-6) activated p21 mRNA expression more than 3 fold.
  • the p21 gene is an important cell cycle negative regulatory gene and therefore has a tumor suppressing effect.
  • PC-3 cells were transfected with p21 dsaRNA and Promega CellTiter was used 72 hours after transfection. Cell viability was analyzed using the AQ ueous One Solution Cell Proliferation Assay kit. As shown in Figure 4, dsaP21-4, dsaP21-5, and dsaP21-6 significantly reduced the survival rate of PC-3 cells. Moreover, this effect is associated with the ability of dsaRNA to promote expression of the p21 gene.
  • PC-3 cells were uniformly cultured in 6-well plates, and dsaRNAs designed to target different sites of p21 promoter were transfected into PC-3 cells, respectively, and blank Mock control group and dsaControl control group were set, and the difference was used after 72 hours. The cells were observed under a microscope. As shown in Fig. 5, the growth rate of PC-3 in the experimental group transfected with dsaP21-4, dsaP21-5, and dsaP21-6 was slowed down, and the number was significantly lower than that of the control group.
  • the number of cells transfected with dsaP21-4 was higher than that of the experimental group transfected with dsaP21-5, and the number of cells in the experimental group transfected with dsaP21-6 was smaller. This indicates that the effect of dsaP21 on cell growth inhibition is closely related to the ability of dsaP21 to promote p21 gene expression. The stronger the ability of dsaP21 to promote p21 gene expression, the stronger its ability to inhibit cell growth. These indicate that this dsaP21 is an effective inhibitor of tumor cell growth inhibition.
  • the present invention demonstrates the activity from the shear of the Dicer enzyme.
  • the substrate saRNA molecule (dsaRNA) of the Dicer enzyme obtained by saRNA can significantly increase the activation efficiency of the target gene.
  • the existing method of the saRNA method is to mimic the product of the dicer enzyme, thereby bypassing its interaction with the Dicer enzyme.
  • the dsaRNAs designed in this patent can improve the efficiency of RNA activation, making the target DNA molecule easier to interact with dsaRNA, thereby facilitating the activation of the target gene more easily and efficiently.
  • dsRNA of 23 nucleotides in length was designed for 6 sites of the p21 gene promoter. They are named: dsP21-1a, dsP21-2a, dsP21-3a, dsP21-4a, dsP21-5a, dsP21-6a.
  • dsP21-1a sense sequence: SEQ ID NO: 30GCUCCAGGUGCUUCUGGGAGAGG, antisense sequence: SEQ ID NO: 31UCUCCCAGAAGCACCUGGAGCAC
  • dsP21-2a sense sequence: SEQ ID NO: 32GUAUUAAUGUCAUCCUCCUGATC, antisense sequence: SEQ ID NO :33UCAGGAGGAUGACAUUAAUACAU
  • dsP21-3a sense sequence: SEQ ID NO: 34CCUGGAGAGUGCCAACUCAUUCU, antisense sequence: SEQ ID NO: 35AAUGAGUUGGCACUCUCCAGGAG
  • a 35-nucleotide dsRNA was designed for 6 sites of the p21 gene promoter, and was named as dsP21-1b, dsP21-2b, dsP21-3b, dsP21-4b, dsP21-5b, dsP21-6b.
  • dsaP21-1b sense sequence: SEQ ID NO: 42GUCUAGGUGCUCCAGGUGCUUCUGGGAGAGGUGAC, antisense sequence: SEQ ID NO: 43CACCUCUCCCAGAAGCACCUGGAGCACCUAGACAC
  • dsaP21-2b sense sequence: SEQ ID NO: 44AUUUUUAUGUAUUAAUGUCAUCCUCCUGAUCUUTT, antisense sequence: SEQ ID NO: 45AAGAUCAGGAGGAUGACAUU AAUACAUA AAAAUTC
  • dsaP21-3b sense sequence is: SEQ ID NO: 46UGUGUCCUCCUGG AGAGUGCCAACUCAUUCCAA, antisense sequence: SEQ ID NO: 47GGAGAAUGAGUUGGCACUCUCCAGGAGGACACAGC
  • dsaP21-4b sense sequence: SEQ ID NO: 48CUAGUGAGGGAUCAGUGGGAAUAGAGGUGAUAUTG, antisense sequence: SEQ ID NO: SEQ ID NO:
  • the dsaRNA designed according to the present invention has a highly efficient expression of the pancreatic-duodenal homeobox gene (PDX1).
  • PDX1 gene is an important gene regulating islet function, and PDX1 can also promote insulin gene expression in non- ⁇ cells such as hepatocytes, which has important application value in the treatment of diabetes.
  • the deoxyribonucleotides in the dsaRNA sequence are represented by lower case bold in the sequence shown below.
  • dsaPDX1-1 (sense sequence: SEQ ID NO: 54 CACACUAUGUCCAUUAUCAAAUA ta, antisense sequence: SEQ ID NO: 55 UAUAUUUGAUAAUGGACAUAGUGUGUU); dsaPDX1-2 (sense sequence: SEQ ID NO: 56CCGACAUCUUUGUGGCUGUGAACaa, antisense sequence: SEQ ID NO: 57UUGUUCACAGCCACAAAGAUGUCGGUU); dsaPDX1-3 (sense sequence: SEQ ID NO: 58GACCUAGAGAGCUGGGUCUGCAAac, antisense sequence: SEQ ID NO: 59GUUUGCAGACCCAGCUCUCUAGGUCAG); dsaPDX1-4 (sense sequence: SEQ ID NO: 60ACAACGAAUGCCAGAGUUUCGUGtg, antisense sequence: SEQ ID NO :61CACACGAAACUCUGGCAUUCGUUGUGU); dsaPDX1-5 (
  • the designed dsaPDX1 was transfected into HepG2 cells respectively, and the concentration of dsaPDX1 RNA was 50 nM. After 96 hours of transfection, the cells were collected, total RNA was extracted, and the expression of PDX1 gene was detected. The results showed that dsaPDX1-1, dsaPDX1-3 and dsaPDX1-4 can efficiently activate the expression of PDX1 gene in HepG2 cells. ( Figure 8).
  • the dsaRNA designed according to the present invention has a highly efficient expression of the NKX3.1 gene.
  • NKX3.1 is a prostate specific and androgen regulating gene. Highly expressed in human prostate tissue, it is a prostate-specific tumor suppressor and plays an important role in the treatment of prostate cancer.
  • the present invention designs dsaRNAs for different sites in the NKX3.1 promoter.
  • the deoxyribonucleotides in the dsaRNA sequence are represented by lower case bold in the sequence shown below.
  • dsaNKX-1 (sense sequence: SEQ ID NO: 70GAGGAGAGCUGGAGAAGGAGAGGaa, antisense sequence: SEQ ID NO: 71UUCCUCUCCUUCUCCAGCUCUCCUCCC); dsaPDX1-2 (sense sequence: SEQ ID NO: 72AGAGCUAACUGGACUGUUUGUCUtg, antisense sequence: SEQ ID NO: 73CAAGACAAACAGUCCAGUUAGCUCUUC); dsaPDX1-3 (sense sequence: SEQ ID NO: 74CUGUAAUUGGCUCUGACGGUCCUGA, antisense sequence: SEQ ID NO: 75UCAGGACCGUCAGAGCCAAUUACAGGG); dsaPDX1-4 (sense sequence: SEQ ID NO: 76AGAGCACCCAGAACUCUCACGGUac, antisense sequence: SEQ ID NO: 77GUACCGUGAGAGUUCUGGGUGCUCUCU); dsaPDX1-5 (sense sequence:
  • the designed dsaNKX was transfected into prostate cancer PC-3 cells respectively, and the concentration of dsaNKX RNA was 50 nM. After 96 hours of transfection, the cells were collected, total RNA was extracted, and the expression of NKX3.1 gene was detected. The results showed that dsaNKX-1, dsaNKX-2, dsaNKX-3, dsaNKX-4 and dsaNKX-5 can efficiently activate the expression of NKX3.1 gene in PC-3 cells, of which dsaNKX-1 and dsaNKX-5 are activated. The effect is more pronounced (Figure 9), which is effective in inhibiting the proliferation of PC-3 cells ( Figure 10).

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Plant Pathology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne un petit ARN activateur (saRNA). Le saRNA consiste en une séquence sens comprenant 25 à 30 nucléotides et une séquence antisens comprenant 25 à 30 nucléotides, au moins 80 % de la séquence antisens étant complémentaire de la séquence sens. La séquence sens ou la séquence antisens comprend des segments qui se correspondent constitués de 19 à 25 nucléotides, la séquence d'au moins 80 % du segment avec correspondance étant complémentaire d'un segment appartenant à une séquence régulatrice d'un gène cible.
PCT/CN2015/074358 2015-03-17 2015-03-17 Petit arn activateur, procédé de fabrication et application de ce dernier Ceased WO2016145608A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/CN2015/074358 WO2016145608A1 (fr) 2015-03-17 2015-03-17 Petit arn activateur, procédé de fabrication et application de ce dernier

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2015/074358 WO2016145608A1 (fr) 2015-03-17 2015-03-17 Petit arn activateur, procédé de fabrication et application de ce dernier

Publications (1)

Publication Number Publication Date
WO2016145608A1 true WO2016145608A1 (fr) 2016-09-22

Family

ID=56919875

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2015/074358 Ceased WO2016145608A1 (fr) 2015-03-17 2015-03-17 Petit arn activateur, procédé de fabrication et application de ce dernier

Country Status (1)

Country Link
WO (1) WO2016145608A1 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021520221A (ja) * 2018-04-10 2021-08-19 ラクティゲン セラピューティクス 新規小分子活性化ｒｎａ
EP3778893A4 (fr) * 2018-04-10 2022-04-20 Ractigen Therapeutics Procédé d'activation de l'expression du gène p21
CN117377764A (zh) * 2021-02-08 2024-01-09 中美瑞康核酸技术(南通)研究院有限公司 多价寡核苷酸试剂及其使用方法
US12605400B2 (en) 2019-04-30 2026-04-21 Ractigen Therapeutics Oligomeric nucleic acid molecule, and application thereof in an acute intermittent porphyria treatment

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100210707A1 (en) * 2005-04-15 2010-08-19 Longcheng Li Small Activating RNA Molecules and Methods of Use
CN102641508A (zh) * 2012-05-01 2012-08-22 浙江大学 靶向上调par-4基因小rna在制备抗膀胱癌药物中的应用
CN102657878A (zh) * 2012-05-01 2012-09-12 浙江大学 Ints6基因小激活rna在制备抗前列腺癌药物中的应用
CN103842508A (zh) * 2011-06-21 2014-06-04 米纳治疗有限公司 白蛋白产生和细胞增殖

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100210707A1 (en) * 2005-04-15 2010-08-19 Longcheng Li Small Activating RNA Molecules and Methods of Use
CN103842508A (zh) * 2011-06-21 2014-06-04 米纳治疗有限公司 白蛋白产生和细胞增殖
CN102641508A (zh) * 2012-05-01 2012-08-22 浙江大学 靶向上调par-4基因小rna在制备抗膀胱癌药物中的应用
CN102657878A (zh) * 2012-05-01 2012-09-12 浙江大学 Ints6基因小激活rna在制备抗前列腺癌药物中的应用

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021520221A (ja) * 2018-04-10 2021-08-19 ラクティゲン セラピューティクス 新規小分子活性化ｒｎａ
EP3778892A4 (fr) * 2018-04-10 2022-01-19 Ractigen Therapeutics Nouveau petit arn activateur
EP3778893A4 (fr) * 2018-04-10 2022-04-20 Ractigen Therapeutics Procédé d'activation de l'expression du gène p21
JP7432521B2 (ja) 2018-04-10 2024-02-16 ラクティゲン セラピューティクス 新規小分子活性化ｒｎａ
US12605400B2 (en) 2019-04-30 2026-04-21 Ractigen Therapeutics Oligomeric nucleic acid molecule, and application thereof in an acute intermittent porphyria treatment
CN117377764A (zh) * 2021-02-08 2024-01-09 中美瑞康核酸技术(南通)研究院有限公司 多价寡核苷酸试剂及其使用方法

Similar Documents

Publication Publication Date Title
EP2925866B1 (fr) Arn circulaire destiné à l'inhibition de micro-arn
CN107177598B (zh) 用于抑制BIRC5靶基因mRNA表达的寡核酸分子及其成套组合物
CN106032532A (zh) 一种小激活rna及其制备方法和应用
JP2015211680A (ja) 遺伝子発現の阻害のためのショートヘアピンｒｎａ
JP2008239596A (ja) マイクロｒｎａを有効成分として含有する腫瘍増殖抑制剤、および癌治療用医薬組成物
WO2016145608A1 (fr) Petit arn activateur, procédé de fabrication et application de ce dernier
JP2020037599A (ja) 新規な治療用抗癌薬の製造及び使用
US20080207539A1 (en) Self-Processing Rna Expression Cassette
US8470998B2 (en) Positive controls for expression modulating experiments
CN104031916B (zh) 新型RNAi前体及其制备和应用
CN100357436C (zh) 抑制Stat3基因表达的siRNA及其制备方法
CN102229928B (zh) 人rbbp6基因的小干扰rna及其应用
Soufi et al. The expression of Drosha, DGCR8, Dicer and Ago-2 genes are upregulated in human umbilical vein endothelial cells under hyperglycemic condition
CN101831461A (zh) 一种人小RNA-148a表达载体及应用
CN101892236B (zh) 靶向znf268基因的rna干扰表达载体构建及应用
WO2006130976A1 (fr) Arn interferents, procedes d'elaboration et utilisation
WO2019000148A1 (fr) Arnsi du gène abcb6 humain et utilisation correspondante
CN107557363A (zh) 可诱导型siRNA表达载体及其制备和应用
WO2017214953A1 (fr) Construction et application d'un vecteur lentiviral pour l'inhibition spécifique de l'expression de l'arnmi-424 humain
JP2009171895A (ja) 核内ノンコーディングｒｎａの機能解析方法
Karpilow et al. siRNA: enhanced functionality through rational design and chemical modification
Ji et al. Construction of Hsp90β gene specific silencing plasmid and its transfection efficiency
CN103937794A (zh) 一种增强基因表达的激活型siRNA
WO2017132945A1 (fr) Conception et application de molécule de promoteur de microarn artificiel

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15884991

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 15884991

Country of ref document: EP

Kind code of ref document: A1